OSLO, Norway--(BUSINESS WIRE)--Ultimovacs AS ('Ultimovacs') has carried out a successful NOK 45 million share issue with DNB Markets and Arctic Securities as financial advisors. The issue was fully subscribed by new shareholders. The two biggest new shareholders are Canica AS ('Canica') and Sundt AS ('Sundt').
Ultimovacs is a biotechnology company that develops a therapeutic universal cancer vaccine. Such cancer treatment is not linked to a specific type of cancer, but has the potential to trigger a general immunologic reaction against cancer cells, regardless of the type of cancer. Stimulating the immune system to attack cancer cells is a revolutionary form of cancer treatment and a treatment principle in rapid international development. Several new treatments based on this principle have already been introduced, and the technology has the potential to greatly improve the treatment options available for cancer. The Norwegian academic communities and companies that belong to Oslo Cancer Cluster are world-leading in this field. Ultimovacs is one such company.
Help employers find you! Check out all the jobs and post your resume.
Ultimovacs is a biotechnology company that develops a therapeutic universal cancer vaccine. Such cancer treatment is not linked to a specific type of cancer, but has the potential to trigger a general immunologic reaction against cancer cells, regardless of the type of cancer. Stimulating the immune system to attack cancer cells is a revolutionary form of cancer treatment and a treatment principle in rapid international development. Several new treatments based on this principle have already been introduced, and the technology has the potential to greatly improve the treatment options available for cancer. The Norwegian academic communities and companies that belong to Oslo Cancer Cluster are world-leading in this field. Ultimovacs is one such company.
Help employers find you! Check out all the jobs and post your resume.
